Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease
Against this backdrop of rising obesity and new pharmacologic strategies, it is critical to note that the majority of patients undergoing orthopedic surgery, particularly joint arthroplasty, meet criteria for obesity (BMI 3039.9) or morbid obesity (BMI 40)
5 , 189 (2016) Acknowledgements This work was supported by the National Natural Science Foundation of China grants 31330019 (Z.-J.L.), 31500593 (G.S.), 81373463 and 81573479 (D.Y.), the National Health and Family Planning Commission grants 2012ZX09304-011, 2013ZX09401003-005, 2013ZX09507001 and 2013ZX09507-002 (M.-W.W.), Shanghai Science and Technology Development Fund 15DZ2291600 (M.-W.W.), and Ministry of Science and Technology of China grants 2014CB910400 (Z.-J.L.) and 2015CB910104 (Z.-J.L.), the Netherlands eScience Center (NLeSC)/NWO Enabling Technologies project: 3D-e-Chem, grant 027.014.201 (C.d.G.), the European Cooperation in Science and Technology Action CM1207 GLISTEN (C.d.G.), and National Key Research and Development Program of China 2016YCF0905902 (S.Z.)
The decision to prescribe Ozempic for weight loss in non-diabetic patients is typically made in a collaborative setting, such as with specialists at Primary Care of Clear Lake
In addition to , and cells in the pancreas, the receptor has been found in a variety of other tissues, including the intestine, stomach, lungs, heart, kidneys and several regions of the central nervous system (Holst et al., 2019
Key factors that may influence bone health during GLP-1 treatment include: Rate and magnitude of weight loss : Losing weight rapidly or losing a substantial percentage of body weight may reduce mechanical stress on bones, potentially leading to decreased bone mineral density
